Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1089-1095

  Cai, Zhiyou ^a   Yan, Yong ^b   Wang, Yonglong ^b  

^a Lu'an People's Hospital   (Taiwan)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

amyloid protein; Diabetes mellitus; Minocycline; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; INTERLEUKIN 1BETA; MINOCYCLINE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HIPPOCAMPUS; LIPID DIET; METABOLIC DISORDER; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOCIN DIABETES; TAUOPATHY; ALZHEIMER DISEASE; ANIMAL; COMPLICATION; IMMUNOLOGY; METABOLISM; NEUROGENIC INFLAMMATION; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DIABETES COMPLICATIONS; FEMALE; HIPPOCAMPUS; INTERLEUKIN-1BETA; MINOCYCLINE; MODELS, ANIMAL; NEUROGENIC INFLAMMATION; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882761023     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S46536     Document Type: Article

References (49)

1. Wang KC, Woung LC, Tsai MT, Liu CC, Su YH, Li CY. Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study. Neuroepidemiology. 2012;38:237-244.
2. Takeda S. Pathological interaction between diabetes mellitus and Alzheimer's disease. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012;32:239-244. Japanese.
3. Kim B, Backus C, Oh S, Feldman EL. Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease. J Alzheimers Dis. 2013;34:727-739.
4. Bartl J, Monoranu CM, Wagner AK, Kolter J, Riederer P, Grunblatt E. Alzheimer's disease and type 2 diabetes: two diseases, one common link? World J Biol Psychiatry. 2013;14:233-240.
5. Pilcher H. Alzheimer's disease could be type 3 diabetes. Lancet Neurol. 2006;5:388-389.
6. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis. 2006;10:89-109.
7. Zhang ZY, Zhang Z, Fauser U, Schluesener HJ. Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral and central inflammation by minocycline. J Cell Mol Med. 2009;13: 341-351.
8. Kuang X, Scofield VL, Yan M, Stoica G, Liu N, Wong PK. Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res. 2009;1286: 174-184.
9. Cai Z, Zhao Y, Yao S, Bin Zhao B. Increases in beta-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-kappaB pathway activation. Pharmacol Rep. 2011;63:381-391.
10. Cai ZY, Yan Y, Chen R. Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull. 2010;26:28-36.
11. Cai ZY, Yan Y, Sun SQ, et al. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. Neurosci Bull. 2008;24:305-313.
12. Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel UL. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis. 2009;16:809-821.
13. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012;9:35-66.
14. Dong SF, Hong Y, Liu M, et al. Berberine attenuates cardiac dysfunc-tion in hyperglycemic and hypercholesterolemic rats. Eur J Pharmacol. 2011;660:368-374.
15. Reed MJ, Meszaros K, Entes LJ, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism. 2000;49: 1390-1394.
16. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF: Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J. 1997;38(1):41-48.
17. Roulston CL, Lawrence AJ, Widdop RE, Jarrott B. Minocycline treatment attenuates microglia activation and non-angiotensin II [125I] CGP42112 binding in brainstem following nodose ganglionectomy. Neuroscience. 2005;135:1241-1253.
18. Ozaki K, Sano T, Tsuji N, Matsuura T, Narama I. Insulin-induced hypoglycemic peripheral motor neuropathy in spontaneously diabetic WBN/Kob rats. Comp Med. 2010;60:282-287.
19. Tze WJ, Tai J, Wong FC, Davis HR. Studies with implantable artificial capillary units containing rat islets on diabetic dogs. Diabetologia. 1980;19:541-545.
20. Bhattacharya P, Pandey AK, Paul S. Minocycline and magnesium in combination may be a good therapeutic intervention for cerebral ischemia. Med Hypotheses. 2011;77:1129-1131.
21. Martin A, Boisgard R, Kassiou M, Dolle F, Tavitian B. Reduced PBR/ TSPO expression after minocycline treatment in a rat model of focal cerebral ischemia: a PET study using [(18)F]DPA-714. Mol Imaging Biol. 2011;13:10-15.
22. Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. The prospects of minocycline in multiple sclerosis. J Neuroimmunol. 2011;235:1-8.
23. Defaux A, Zurich MG, Honegger P, Monnet-Tschudi F. Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-gamma plus lipopolysaccharide-induced demyelination. Neuroscience. 2011;187:84-92.
24. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003;53:267-270.
25. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045-1053.
26. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis. 2004;17:359-366.
27. Bantubungi K, Jacquard C, Greco A, et al. Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis. 2005;18:206-217.
28. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol. 2004;3:744-751.
29. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopamin-ergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98:14669-14674.
30. Amlien IK, Fjell AM, Walhovd KB, et al. Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. Radiology. 2013;266:295-303.
31. Parnetti L, Chiasserini D, Eusebi P, et al. Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis. 2012;29:229-238.
32. Lomoio S, Scherini E, Necchi D. Beta-amyloid overload does not directly correlate with SAPK/JNK activation and tau protein phospho-rylation in the cerebellar cortex of Ts65Dn mice. Brain Res. 2009;1297: 198-206.
33. Mohandas E, Rajmohan V, Raghunath B. Neurobiology of Alzheimer's disease. Indian J Psychiatry. 2009;51:55-61.
34. Papon MA, El Khoury NB, Marcouiller F, et al. Deregulation of protein phosphatase 2A and hyperphosphorylation of tau protein following onset of diabetes in NOD mice. Diabetes. 2013;62:609-617.
35. Wang Y, Cheng Z, Qin W, Jia J. Val97 Leu mutant presenilin-1 induces tau hyperphosphorylation and spatial memory deficit in mice and the underlying mechanisms. J Neurochem. 2012;121:135-145.
36. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26-35.
37. Liu Y, Su Y, Wang J, et al. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int. 2013;62:458-467.
38. Keller AF, Gravel M, Kriz J. Treatment with minocycline after dis-ease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol. 2011;228:69-79.
39. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol. 2005;78:135-143.
40. Si Q, Cosenza M, Kim MO, et al. A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol. 2004;10:284-292.
41. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001;21:2580-2588.
42. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocy-cline in vivo and in vitro. Stroke. 2006;37:1087-1093.
43. Parthsarathy V, Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 2013;700:42-50.
44. Celik S, Erdogan S. Caffeic acid phenethyl ester (CAPE) protects brain against oxidative stress and inflammation induced by diabetes in rats. Mol Cell Biochem. 2008;312:39-46.
45. Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox Res. 2013;23:131-144.
46. Pintado C, Gavilan MP, Gavilan E, et al. Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus. J Neuroinflammation. 2012;9:87.
47. Craft JM, Watterson DM, Van Eldik LJ. Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia. 2006;53:484-490.
48. Cai Z, Zhao B, Ratka A. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neuromolecular Med. 2011;13:223-250.
49. Texel SJ, Mattson MP. Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's disease. Antioxid Redox Signal. 2011;14:1519-1534.